AMRN - Amarin Corp PLC Stock Price, Fair Value and News

0.80USD+0.01 (+1.27%)Market Closed

Market Summary

USD0.80+0.01

Market Closed

1.27%

AMRN Stock Price

View Fullscreen

AMRN RSI Chart

AMRN Valuation

Market Cap

328.6M

Price/Earnings (Trailing)

-6.25

Price/Sales (Trailing)

1.18

EV/EBITDA

-2.4

Price/Free Cashflow

255.31

AMRN Price/Sales (Trailing)

AMRN Profitability

EBT Margin

-17.24%

Return on Equity

-9.64%

Return on Assets

-6.66%

Free Cashflow Yield

0.39%

AMRN Fundamentals

AMRN Revenue

Revenue (TTM)

277.5M

Rev. Growth (Yr)

-34.26%

Rev. Growth (Qtr)

-24.35%

AMRN Earnings

Earnings (TTM)

-52.6M

Earnings Growth (Yr)

39.53%

Earnings Growth (Qtr)

-72.17%

Breaking Down AMRN Revenue

Last 7 days

2.6%

Last 30 days

14.3%

Last 90 days

-8.0%

How does AMRN drawdown profile look like?

AMRN Financial Health

Current Ratio

3.07

Debt/Equity

0.02

Debt/Cashflow

0.14

AMRN Investor Care

Shares Dilution (1Y)

1.12%

Diluted EPS (TTM)

-0.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	277.5M	0	0	0
2023	360.5M	346.3M	322.4M	306.9M
2022	535.6M	475.6M	423.4M	369.2M
2021	601.2M	620.4M	605.9M	583.2M
2020	511.5M	546.0M	590.1M	614.1M
2019	258.6M	306.7M	363.8M	429.8M
2018	190.4M	197.8M	205.8M	229.2M
2017	139.2M	151.3M	165.9M	181.1M
2016	91.4M	106.8M	118.0M	130.1M
2015	59.2M	64.3M	71.6M	81.8M
2014	35.0M	42.1M	47.8M	54.2M
2013	0	0	0	26.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Amarin Corp PLC

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

CEO	Mr. Patrick Holt
WEBSITE	amarincorp.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	365

Amarin Corp PLC Frequently Asked Questions

What is the ticker symbol for Amarin Corp PLC? What does AMRN stand for in stocks?

AMRN is the stock ticker symbol of Amarin Corp PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amarin Corp PLC (AMRN)?

As of Fri Jul 26 2024, market cap of Amarin Corp PLC is 328.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRN stock?

You can check AMRN's fair value in chart for subscribers.

Is Amarin Corp PLC a good stock to buy?

The fair value guage provides a quick view whether AMRN is over valued or under valued. Whether Amarin Corp PLC is cheap or expensive depends on the assumptions which impact Amarin Corp PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRN.

What is Amarin Corp PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AMRN's PE ratio (Price to Earnings) is -6.25 and Price to Sales (PS) ratio is 1.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRN PE ratio will change depending on the future growth rate expectations of investors.